P. Rose

F. Abdul-Karim, E. Brandewie, P. Rose, 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Lifestyle Challenges in Endometrial Cancer Survivorship

K. Courneya, S. Waggoner, P. Rose, 2011, Obstetrics and gynecology.

Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): a randomized controlled trial.

K. Courneya, S. Waggoner, P. Rose, 2012, Gynecologic oncology.

Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists: a prospective cohort study.

P. Schauer, P. Rose, C. Michener, 2015, American journal of obstetrics and gynecology.

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.

M. Shahin, R. Coleman, P. Rose, 2011, Gynecologic oncology.

Fertility-Sparing Surgery for Early-Stage Cervical Cancer: A Systematic Review of the Literature.

L. Chambers, P. Rose, M. Kuznicki, 2020, Journal of minimally invasive gynecology.

Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center.

C. Eng, A. Roma, Bin Yang, 2013, Gynecologic oncology.

Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer.

L. Chambers, P. Rose, R. Vargas, 2021, Gynecologic oncology.

Racial Disparity in 30-Day Morbidity and Mortality After Surgery for Ovarian Cancer

P. Rose, H. Mahdi, D. Lockhart, 2015, International Journal of Gynecologic Cancer.

Impact of Age on 30-Day Mortality and Morbidity in Patients Undergoing Surgery for Ovarian Cancer

P. Rose, H. Mahdi, D. Lockhart, 2015, International Journal of Gynecologic Cancer.

Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.

A. Fader, P. Rose, M. Markman, 2008, Gynecologic oncology.

Conservative therapy for melanoma of the vulva.

M. Piver, P. Rose, Y. Tsukada, 1988, American journal of obstetrics and gynecology.

Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.

B. Monk, D. Cella, P. Rose, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thallium isotope scintigraphy and ultrasonography: Comparative studies of localization techniques in primary hyperparathyroidism

J. Farndon, P. Rose, G. Carlson, 1990, British Journal of Surgery.

Surgical staging of gynecologic malignancies: the role of laparoscopy and sentinel node technology.

P. Rose, R. Kim, 2005, Surgical oncology clinics of North America.

Brachytherapy for early endometrial carcinoma: a comparative study with long-term follow-up.

T. Fitzgerald, P. Rose, F. Reale, 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Endometrial carcinoma [3] (multiple letters)

P. Rose, J. R. Lee, A. Verhoeven, 1997 .

Primary radiation therapy for endometrial carcinoma: a case controlled study.

T. Fitzgerald, S. Baker, P. Rose, 1993, International journal of radiation oncology, biology, physics.

Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma.

T. Fitzgerald, P. Rose, F. Reale, 1992, International journal of radiation oncology, biology, physics.

Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.

D. Gershenson, P. Rose, J. Blessing, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel a nd C isplatin a s F irst-Line T herapy i n R ecurrent or A dvanced S quamous C ell C arcinoma o f t he C ervix: A G ynecologic O ncology G roup S tudy

D. Gershenson, P. Rose, J. Blessing, 1999 .

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

B N Bundy, M. Maiman, J. Thigpen, 1999, The New England journal of medicine.

Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.

D. Alberts, M. Parmar, L. Stewart, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study.

P. Rose, S. McMeekin, K. Degeest, 2007, Gynecologic oncology.

The flower looks as good as its bud.

P. Rose, 2007, American journal of obstetrics and gynecology.

Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer.

P. Rose, D. O’Malley, A. Ludin, 2004, Gynecologic oncology.

Innovations in the treatment of invasive cervical cancer

F. Montz, J. Wharton, P. Rose, 2003, Cancer.

Chemoradiation for locally advanced cervical cancer: does it help?

P. Rose, B. Bundy, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoradiotherapy: the new standard care for invasive cervical cancer.

P. Rose, 2000 .

Ovarian cancer, version 1.2016: Clinical practice guidelines in oncology

P. Sabbatini, E. Ratner, L. Havrilesky, 2016 .

Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.

P. Rose, M. Rodríguez, Michael Rodriguez, 2001, Gynecologic oncology.

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.

M. Morgan, T. Herzog, P. Rose, 1999, Gynecologic oncology.

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

C. Hoppel, P. Rose, S. Ingalls, 2000, Gynecologic oncology.

Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

R. Mannel, N. Susumu, P. Rose, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Coarctation of the aorta as a cause of spinal subarachnoid hemorrhage. Case report.

P. Rose, M. Banna, G. Pearce, 1973, Journal of neurosurgery.

Signaling within the epithelial ovarian cancer tumor microenvironment: the challenge of tumor heterogeneity.

E. Esakov, P. Rose, O. Reizes, 2020, Annals of translational medicine.

Role of Gemcitabine in the Treatment of Ovarian Cancer

P. Rose, Fadi Abushahin, F. Abushahin, 2007, Women's health.

Gemcitabine reverses platinum resistance in platinum‐resistant ovarian and peritoneal carcinoma

P. Rose, 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma

P. Rose, 2004, International Journal of Gynecologic Cancer.

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.

P. Rose, M. Smrekar, N. Fusco, 2003, Gynecologic oncology.

Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity.

P. Rose, M. Smrekar, N. Fusco, 2003, Gynecologic oncology.

Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer

F. Abdul-Karim, J. Lathia, C. Braley, 2019, Journal of Ovarian Research.

Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.

L. Chambers, P. Rose, C. Michener, 2020, Journal of gynecology obstetrics and human reproduction.

Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer.

P. Rose, R. Debernardo, A. Pendlebury, 2017, Anti-cancer drugs.

Pegylated liposomal doxorubicin in ovarian cancer

P. Rose, A. Green, 2006, International journal of nanomedicine.

Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

A. Secord, T. Rutherford, T. Herzog, 2017, Gynecologic oncology.

Retrospective Analysis of Concomitant Cisplatin During Radiation in Patients Aged 55 Years or Older for Treatment of Advanced Cervical Cancer: A Gynecologic Oncology Group Study

S. Waggoner, P. Rose, C. Tian, 2009, International Journal of Gynecologic Cancer.

Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report.

G. Wiesner, P. Rose, R. Shrigley, 2000, Gynecologic oncology.

Abnormal Cervical Cytology in the Diagnosis of Uterine Papillary Serous Carcinoma: Earlier Detection of a Poor Prognostic Cancer Subtype

A. Fader, P. Rose, S. Ueda, 2011, Acta Cytologica.

First-Line Chemotherapy for Ovarian Cancer: Inferences From Recent Studies.

P. Rose, 2016, The oncologist.

CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers

R. Ozols, D. Spriggs, R. Zaino, 2009, Cancer.

Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.

P. Rose, M. Markman, I. Horowitz, 2007, Gynecologic oncology.

Secondary surgical cytoreduction for advanced ovarian carcinoma.

S. Rubin, M. Brady, P. Rose, 2004, The New England journal of medicine.

Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.

P. Escobar, P. Rose, M. Markman, 2004, Gynecologic oncology.

Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.

P. Rose, M. Smrekar, 2003, Gynecologic oncology.

Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.

S. Waggoner, P. Rose, I. Horowitz, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tolerance of twenty-four hour paclitaxel and carboplatin as first-line therapy in ovarian, peritoneal and fallopian tube carcinoma.

P. Rose, N. Fusco, L. Fluellen, 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.

P. Rose, I. Horowitz, W. Mcguire, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal therapy of ovarian cancer with Yttrium-90-labeled monoclonal antibodies : preliminary observations

P. Rose, T. Griffin, M. Rusckowski, 1991 .

The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone

F. Abdul-Karim, P. Rose, H. Mahdi, 2015, Journal of gynecologic oncology.

Prostate-Type Adenocarcinoma in Mature Cystic Ovarian Teratoma

A. Roma, P. Rose, D. Shepard, 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials.

B. Monk, P. Rose, C. Tian, 2007, Gynecologic oncology.

Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma

L. Chambers, P. Rose, R. Vargas, 2021, Gynecologic oncology reports.

Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis.

L. Chambers, P. Rose, X. Jia, 2020, Gynecologic oncology.

Combined radiation therapy and chemotherapy for carcinoma of the cervix.

P. Rose, P. Eifel, 2001, Cancer journal.

Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?

I. Shih, Tian-Li Wang, Bin Yang, 2016, Gynecologic oncology.

Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma

P. Rose, C. Michener, M. Radeva, 2017, International Journal of Gynecologic Cancer.

p53 expression in neoplasms of the uterine corpus.

L. Edelmann, M. Bur, P. Rose, 1992, American journal of clinical pathology.

The impact of CA-125 on the sensitivity of abdominal/pelvic CT scan before second-look laparotomy in advanced ovarian carcinoma

P. Rose, F. Reale, K. Reuter, 1996 .

Plasma D‐dimer and peritoneal CA‐125 levels as predictors of disease status in ovarian carcinoma

P. Rose, J. Terrien, S. Baker, 1994, Journal of surgical oncology.

Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

P. Rose, S. Lele, O. Abulafia, 2006, Gynecologic oncology.

A phase II, open-label study of ispinesib (SB-715992) in patients with platinum/taxane refractory or resistant relapsed ovarian cancer

R. Buller, M. Shahin, R. Alvarez, 2007 .

Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer.

L. Chambers, P. Rose, R. Vargas, 2021, Gynecologic oncology.

Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.

L. Chambers, P. Rose, R. Vargas, 2020, Gynecologic oncology.

The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy

P. Rose, H. Mahdi, B. Nutter, 2015, International Journal of Gynecologic Cancer.

Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence.

P. Rose, R. Hunter, B. E. Nelson, 1993, American journal of obstetrics and gynecology.

Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.

B. Monk, A. Jazaeri, R. Wenham, 2019, Journal of Clinical Oncology.

Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

L. Chambers, P. Rose, R. Vargas, 2021, Gynecologic oncology.

Landmark studies of therapeutic vaccination in cervical and ovarian cancers.

P. Rose, H. Mahdi, 2020, The Lancet. Oncology.

Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry

L. Chambers, P. Rose, C. Michener, 2021, International Journal of Gynecological Cancer.

The effect of indomethacin on acute radiation induced gastrointestinal injury: A morphologic study

P. Rose, S. Halter, C. Su, 1992, Journal of surgical oncology.

Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population☆

A. Joehlin-Price, P. Rose, H. Mahdi, 2020, Gynecologic oncology reports.

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

P. Sabbatini, E. Ratner, L. Havrilesky, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors

J. Lathia, E. Esakov, C. Braley, 2020, bioRxiv.

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer

B. Monk, A. Secord, J. Chan, 2022, Gynecologic oncology.

Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

L. Chambers, P. Rose, C. Michener, 2021, Gynecologic oncology.

A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study.

B. Monk, D. Cella, K. Gil, 2010, Journal of pain and symptom management.

Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials

B. Monk, D. Cella, P. Rose, 2009, Cancer.

Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.

K. Moxley, A. Fader, P. Rose, 2007, Gynecologic oncology.

Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma

Bin Yang, P. Rose, H. Mahdi, 2016, International Journal of Gynecologic Cancer.

Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma.

A. Roma, P. Rose, 2013, Anti-cancer drugs.

A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.

P. Fracasso, A. Wolfson, P. Rose, 2012, Gynecologic oncology.

Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.

R. Wenham, T. Herzog, B. Childs, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Histologic Follow-up of Atypical Endocervical Cells

F. Abdul-Karim, P. Rose, S. Emancipator, 2002, Acta Cytologica.

Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.

A. Secord, L. Havrilesky, P. Gehrig, 2009, Gynecologic oncology.

Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.

P. Rose, 2022, Obstetrics and gynecology.

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

Andrew K Godwin, A. Godwin, K. Leslie, 2012, Gynecologic oncology.

Effect of Prophylactic Extended‐Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas

P. Rose, Amy L. Pasternak, Nicholas A Link, 2016, Pharmacotherapy.

Clinically meaningful quality-of-life changes in ovarian cancer: Results from gynecologic oncology group clinical trial 152

B. Monk, D. Cella, P. Rose, 2003 .

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?

L. Chambers, P. Rose, M. Kuznicki, 2021, Gynecology & obstetrics.

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

R. Mannel, P. Rose, M. Hensley, 2008, Gynecologic oncology.

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.

J. Lucci, P. Rose, A. Sandler, 2004, Gynecologic oncology.

Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.

P. Rose, J. Soper, J. Blessing, 1998, Gynecologic oncology.

Fertility-Preserving Surgical Procedures for Patients With Gynecologic Malignancies

P. Rose, N. Rasool, 2010, Clinical obstetrics and gynecology.

Serial Serum CA 125 Measurements for Evaluation of Recurrence in Patients With Endometrial Carcinoma

P. Rose, F. Reale, R. Hunter, 1994, Obstetrics and gynecology.

A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology.

L. Chambers, P. Rose, R. Vargas, 2020, Gynecologic oncology.

High‐dose, short‐duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer

T. Fitzgerald, P. Rose, F. Reale, 1991, Cancer.

EORTC 55971: does it apply to all patients with advanced state ovarian cancer?

M. Brady, P. Rose, 2011, Gynecologic oncology.

Second-look operation improves survival in suboptimal, debulked, stage III ovarian cancer.

P. Escobar, P. Rose, C. Michener, 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

The Impact of Combined Radiation and Chemotherapy on Outcome in Uterine Clear Cell Carcinoma Compared with Chemotherapy Alone.

P. Rose, H. Mahdi, B. Nutter, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.

S. Waggoner, P. Rose, A. Munkarah, 2015, Gynecologic oncology.

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

P. Rose, M. Hensley, O. Abulafia, 2008, Gynecologic oncology.

Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.

P. Rose, M. Markman, J. Bell, 2006, Gynecologic oncology.

Accuracy of frozen-section diagnosis at surgery in clinical stage I and II endometrial carcinoma.

P. Rose, F. Reale, J. Shim, 1992, American journal of obstetrics and gynecology.

Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer—A Potential Relationship

P. Rose, H. Mahdi, A. Jernigan, 2015, International Journal of Gynecologic Cancer.

Patterns of metastasis in uterine sarcoma. An autopsy study.

M. Piver, P. Rose, Y. Tsukada, 1989, Cancer.

Use of Prophylactic Closed Incision Negative Pressure Therapy Is Associated with Reduced Surgical Site Infections in Gynecologic Oncology Patients Undergoing Laparotomy.

L. Chambers, P. Rose, R. Vargas, 2020, American journal of obstetrics and gynecology.

Concurrent chemoradiation for locally advanced carcinoma of the cervix: where are we in 2006?

P. Rose, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma.

P. Rose, C. Kunos, J. Belinson, 2009, American journal of obstetrics and gynecology.

Chemotherapy in the treatment of locally advanced cervical cancer during pregnancy.

P. Rose, 2001, Gynecologic oncology.

Chemoradiotherapy

P. Rose, 2012, Drugs.

New standard of care for invasive cervical cancer?

P. Rose, 1999 .

Surgical versus radiographic determination of para‐aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma

P. Rose, C. Tian, C. Whitney, 2008, Cancer.

Combination therapy: New treatment paradigm for locally advanced cervical cancer?

P. Rose, 2011, Nature Reviews Clinical Oncology.

Isolated appendiceal metastasis in early ovarian carcinoma

F. Abdul-Karim, P. Rose, Fadi W. Abdul‐Karim, 1997, Journal of surgical oncology.

Appendectomy in primary and secondary staging operations for ovarian malignancy

P. Rose, F. Reale, R. Hunter, 1991, Obstetrics and gynecology.

Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value.

P. Rose, 2003, Obstetrics and gynecology.

Multiple primary gynecologic neoplasms in a young HIV‐positive patient

A. Fraire, P. Rose, 1993, Journal of surgical oncology.

A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) Study.

K. Leslie, C. Aghajanian, M. Barnes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.

Joan L. Walker, P. Rose, W. Mcguire, 2002, Gynecologic oncology.

Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.

P. Rose, N. Fusco, M. Rodríguez, 2001, Gynecologic oncology.

Patterns of metastasis in uterine sarcoma. An autopsy study

P. Rose, Y. Tsukada, M. Steven Piver, 1989, Cancer.

Fallopian tube cancer: The roswell park experience

M. Piver, P. Rose, Y. Tsukada, 1990, Cancer.

Outcome of Recurrent Uterine Papillary Serous Carcinoma Treated With Platinum-Based Chemotherapy

P. Rose, H. Mahdi, A. Rizzo, 2014, International Journal of Gynecologic Cancer.

Docetaxel in ovarian cancer

P. Escobar, P. Rose, 2005, Expert opinion on pharmacotherapy.

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival

P. Escobar, A. Fader, P. Rose, 2013, Obstetrics and gynecology international.

Serum squamous cell carcinoma antigen levels in invasive squamous vulvar cancer

P. Rose, R. Hunter, B. E. Nelson, 1992, Journal of surgical oncology.

Prognostic Significance of Estrogen and Progesterone Receptors in Epithelial Ovarian Cancer

C. Longcope, P. Rose, R. Hunter, 1990, Obstetrics and gynecology.

A phase II study of weekly cisplatin followed by cisplatin and ifosfamide in advanced or recurrent cervical carcinoma

M. Piver, P. Rose, F. Recio, 1993, Cancer.

A phase II trial of edatrexate in previously treated squamous cell cervical cancer: a Gynecologic Oncology Group study.

R. Mannel, P. Rose, E. R. Broun, 1997, American journal of clinical oncology.

Type II radical hysterectomy: evaluating its role in cervical cancer.

P. Rose, 2001, Gynecologic oncology.

Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer.

P. Escobar, P. Rose, M. Liotta, 2009, Gynecologic oncology.

Role of surgery in ovarian carcinoma.

A. Fader, P. Rose, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Probable Nafcillin—Warfarin Interaction

P. Rose, A. M. Baciewicz, A. Heugel, 1999 .

Fetomaternal hemorrhage following trauma.

F. Zuspan, P. Rose, P. Strohm, 1985, American journal of obstetrics and gynecology.

False-positive elevation of CA-125 in papillary serous carcinoma of the endometrium treated with postoperative whole abdominal radiation.

P. Rose, F. Reale, B. E. Nelson, 1992, Gynecologic oncology.

PROGNOSTIC VALUE OF PRETREATMENT CA-125 IN ADVANCED OVARIAN CARCINOMA: A GYNECOLOGIC ONCOLOGY GROUP STUDY

R. Ozols, D. Spriggs, P. Rose, 2009 .

Desensitization With Oxaliplatin in Patients Intolerant of Carboplatin Desensitization

P. Rose, C. Metz, N. Link, 2014, International Journal of Gynecologic Cancer.

Re: annual report to the nation on the status of cancer (1973 through 1998), featuring cancer with recent increasing trends.

M. Thun, P. Wingo, H. Howe, 2001, Journal of the National Cancer Institute.

Skin bridge recurrences in vulvar cancer: frequency and management.

P. Rose, 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

500 Amifostine (AMI) selectively protects against cumulative toxicities of cyclophosphamide (C) and cisplatin (P)

P. Schein, W. Oster, D. Belpomme, 1995 .

Malignant pericardial effusion from squamous cell cancer of the cervix

P. Rose, B. E. Nelson, 1993, Journal of surgical oncology.

Postoperative Complications After Distal Pancreatectomy Performed During Cytoreductive Surgery for Gynecologic Malignancies

P. Rose, C. Michener, H. Mahdi, 2015, International Journal of Gynecologic Cancer.

Accuracy of frozen-section (intraoperative consultation) diagnosis of ovarian tumors.

P. Rose, F. Reale, R. Hunter, 1994, American journal of obstetrics and gynecology.

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

R. Ozols, P. Rose, F. Muggia, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

P. Rose, W. Creasman, J. Blessing, 1996, Gynecologic oncology.

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

R. Burger, M. Birrer, D. Mutch, 2017, Gynecologic oncology.

Progress in the management of gynecologic cancer: consensus summary statement.

R. Bast, S. Skates, J. Garber, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Change in International Federation of Gynecology and Obstetrics staging.

M. Piver, P. Rose, M. Freedman, 1988, American journal of obstetrics and gynecology.

A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Joan L. Walker, P. Rose, R. B. Lee, 2000, Gynecologic oncology.

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.

J. Glick, D. Belpomme, P. Rose, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).

B. Monk, Jubilee Brown, A. Secord, 2015, Gynecologic oncology.

Fine needle aspiration of ovarian masses. II. Correlative cytologic and histologic study of nonneoplastic cysts and noncelomic epithelial neoplasms.

I. Ramzy, P. Rose, M. Delaney, 1979, Acta cytologica.

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

P. Thaker, K. Moxley, R. Zuna, 2014, Gynecologic oncology.

Malignant mixed mullerian tumor of the female peritoneum: treatment and outcome of three cases.

F. Abdul-Karim, P. Rose, M. Rodríguez, 1997, Gynecologic oncology.

Peritoneal Washing Cytology of Ovarian Tumors of Low Malignant Potential

Liang Cheng, F. Abdul-Karim, P. Rose, 1998, Acta Cytologica.

Cervical Cytology Practice Guidelines

Soo Yong Lee, L. Truong, M. Ostrowski, 2001, Acta Cytologica.

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.

P. Fracasso, L. Landrum, P. DiSilvestro, 2015, Gynecologic oncology.

Trial design for evaluation of novel targeted therapies.

P. Rose, J. Farley, 2010, Gynecologic oncology.

Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion

P. Rose, C. Michener, H. Mahdi, 2015, Journal of gynecologic oncology.

CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors

F. Abdul-Karim, A. Difeo, J. Kim, 2017, bioRxiv.

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

D. Levine, D. Mutch, A. Secord, 2021, Gynecologic oncology.

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition

A. Joehlin-Price, P. Rose, A. Vlad, 2021, npj Precision Oncology.

Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.

Bin Yang, N. Horowitz, P. Rose, 2015, Gynecologic oncology.

Management Strategies for Recurrent Endometrial Cancer

P. Rose, E. Connor, 2018, Expert review of anticancer therapy.

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

J A Blessing, P. Rose, P G Rose, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonendometrioid Endometrial Carcinomas and Uterine Sarcomas

P. Rose, C. Biscotti, 2012 .

Adjuvant therapy for stage I uterine sarcoma.

P. Rose, J. Boutselis, L. Sachs, 1987, American journal of obstetrics and gynecology.

CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.

R. Ganapathi, P. Elson, A. Fader, 2010, Anticancer research.

Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study

J. Thigpen, Shamshad Ali, P. Rose, 2007 .

Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.

H. Averette, M. Varia, R. Mannel, 1998, International journal of radiation oncology, biology, physics.

Disruption of the gut microbiota attenuates epithelial ovarian cancer sensitivity to cisplatin therapy

Jan Claesen, J. M. Brown, J. Lathia, 2020, bioRxiv.

Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

I. Vergote, J. Keck, C. Runowicz, 2010, International Journal of Gynecologic Cancer.

Role of pegylated liposomal doxorubicin in ovarian cancer.

D. Alberts, B. Monk, C. Aghajanian, 2005, Gynecologic oncology.

Isolated parenchymal splenic metastasis in epithelial ovarian cancer.

P. Rose, F. Reale, B. E. Nelson, 1993, Gynecologic oncology.

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

K. Leslie, C. Aghajanian, M. Barnes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

S. Rubin, P. Rose, F. Muggia, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serous papillary carcinoma of the cervix.

P. Rose, F. Reale, 1993, Gynecologic oncology.

A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.

B. Monk, R. Wenham, M. Einstein, 2014, Gynecologic oncology.

Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.

M. Morgan, M. Egorin, R. Mannel, 2008, Gynecologic oncology.

A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.

A. Secord, L. Havrilesky, P. Gehrig, 2012, Gynecologic oncology.

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma

L. Chambers, A. Joehlin-Price, P. Rose, 2021, Gynecologic oncology reports.

A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.

S. Rubin, P. Rose, K. Darcy, 2012, Gynecologic oncology.

Management of locally advanced cervical cancer

P. Rose, L. Rojas-Espaillat, 2005, Current opinion in oncology.

Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment.

P. Rose, T. Krivak, H. Ehrenberg, 2012, Gynecologic oncology.

The relevance of rising CA-125 levels within the normal range in predicting recurrence in patients with advanced stage ovarian cancer: A validation study.

P. Escobar, P. Schwartz, P. Rose, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are the differences in treatment outcome for adenocarcinoma of the cervix different enough to change the treatment paradigm?

P. Rose, 2012, Gynecologic oncology.

Hysteroscopic dissemination of endometrial carcinoma.

I. Kornbluth, P. Rose, G. Mendelsohn, 1998, Gynecologic oncology.

Hydatidiform mole: diagnosis and management.

P. Rose, 1995, Seminars in oncology.

Metastatic patterns in histologic variants of ovarian cancer. An autopsy study

M. Piver, P. Rose, Y. Tsukada, 1989, Cancer.

Alternating methotrexate and dactinomycin in nonmetastatic gestational trophoblastic disease

P. Rose, M. Steven Piver, Rose Pg, 1989, Journal of surgical oncology.

An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).

A. Secord, L. Havrilesky, P. Gehrig, 2009, Gynecologic oncology.

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.

K. Swenerton, E. Ette, G. Batist, 2002, Gynecologic oncology.

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

T. Grogan, P. Fracasso, M. Brady, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radical abdominal trachelectomy and pelvic lymphadenectomy with uterine conservation and subsequent pregnancy in the treatment of early invasive cervical cancer.

P. Rose, M. Rodríguez, O. Guimares, 2002, American journal of obstetrics and gynecology.

Primary squamous cell carcinoma of the endometrium: Two cases and a review of the literature

G. Sutton, P. Rose, J. Broshears, 2013, Diagnostic cytopathology.

Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.

P. Rose, C. Tian, M. Bookman, 2010, Gynecologic oncology.

Incidence of squamous cell carcinomas of the head and neck following prolonged pegylated liposomal doxorubicin

L. Chambers, P. Rose, E. Lamarre, 2020, Anti-cancer drugs.

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

D. Alberts, S. Rubin, H. Gray, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.

G. Budd, P. Rose, R. Drake, 2016, Anticancer research.

Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.

L. Chambers, P. Rose, M. Yao, 2020, Gynecologic oncology.

Lymphocyte-specific Protein Tyrosine Kinase Regulates Homologous Recombination (HR) DNA Repair and Targeting Enhances PARPi Utility in HR Proficient Ovarian Cancer

K. McCrae, J. Lathia, E. Esakov, 2021 .

Pure cutaneous histiocytosis X of the vulva.

R. O’Toole, P. Rose, G. C. Johnston, 1984, Obstetrics and gynecology.

Measuring the fetal kidney with ultrasonography.

P. Rose, J. Scott, G. Wilson, 1995, British journal of urology.

Calcifications in Metastases from Adenocarcinoma of the Colon

P. Rose, 1973, Acta radiologica: diagnosis.

Case Report: Circulating Tumor DNA Fraction Analysis Using Ultra-Low-Pass Whole-Genome Sequencing Correlates Response to Chemoradiation and Recurrence in Stage IV Small-Cell Carcinoma of the Cervix - A Longitudinal Study

A. Joehlin-Price, P. Rose, H. Mahdi, 2021, Frontiers in Oncology.

Advanced ovarian carcinoma managed in an HIV-positive patient.

P. Rose, S. Cheeseman, 1993, Gynecologic oncology.

Adverse post-operative outcomes in Jehovah's witnesses with gynecologic cancer within 30 days of surgery: A single institution review of 36 cases☆

P. Rose, H. Mahdi, L. Moulton, 2017, Gynecologic oncology reports.

A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).

P. Escobar, P. Rose, N. Rasool, 2015, Gynecologic oncology.

Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma

Shamshad Ali, P. Rose, F. Simpkins, 2016, International Journal of Gynecologic Cancer.

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

J. Hainsworth, P. Rose, C. Granai, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.

J. Java, P. Rose, G. Thomas, 2014, Gynecologic oncology.

Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.

P. Rose, P. Rose, Peter G. Rose, 2005, The oncologist.

PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer

L. Chambers, P. Rose, R. Vargas, 2021, Anti-cancer drugs.

Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.

A. Secord, K. Moxley, A. Fader, 2010, Gynecologic oncology.

Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis.

D. Alberts, M. Parmar, L. Stewart, 2010, The Cochrane database of systematic reviews.

Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.

P. Fracasso, J. Sorosky, P. Rose, 2006, Gynecologic oncology.

Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: the MIID-SOC trial

L. Chambers, P. Rose, C. Michener, 2021, Gynecologic Oncology.

Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.

P. Rose, 1996, Seminars in oncology.

Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study.

P. Rose, M. Elshaikh, K. Albuquerque, 2015, Gynecologic oncology.

Atypical Squamous Cells of Undetermined Significance in Women Over 55

F. Abdul-Karim, P. Rose, A. Rader, 1999, Acta Cytologica.

Chemoradiation for cervical cancer

P. Rose, H. Mahdi, 2015 .

Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study.

L. Adler, F. Abdul-Karim, P. Rose, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoradiotherapy for cervical cancer.

P. Rose, 2002, European journal of cancer.

Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.

James Java, P. DiSilvestro, J. Java, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experience

C. Reddy, P. Rose, C. Michener, 2020, Journal of radiosurgery and SBRT.

Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study.

Shamshad Ali, P. Rose, C. Whitney, 2010, Gynecologic oncology.

Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group study.

Shamshad Ali, P. Rose, Peter G Rose, 2011, Gynecologic oncology.

Malignant melanoma of the vulva: an extension of cutaneous melanoma?

D. Mutch, D. Chi, K. Moxley, 2011, Gynecologic oncology.

Symptomatic vaginal bleeding in a postmenopausal woman: a case report of pancreatic adenocarcinoma metastasizing exclusively to the vagina.

A. Fader, P. Rose, J. Brainard, 2007, American journal of obstetrics and gynecology.

Combined-modality therapy of locally advanced cervical cancer.

P. Rose, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Risk-Reducing Salpingo-Oophorectomy on Sex-Steroid Hormone Serum Levels among Post-Menopausal Women: An NRG Oncology/GOG Study.

Katherine M. Tucker, A. Stuckey, M. Greene, 2022, American journal of obstetrics and gynecology.

Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC)

T. Kolevska, C. Runowicz, G. Brown, 2007 .

A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.

J. Beeler, P. Rose, M. Smrekar, 2005, Gynecologic oncology.

Acute Encephalopathy Due to Aluminum Toxicity Successfully Treated by Combined Intravenous Deferoxamine and Hemodialysis

P. Rose, Hidefumi Nakamura, J. Blumer, 2000, Journal of clinical pharmacology.

Operative retroperitoneal ureteral catheterization for obstructive uropathy in primary locally advanced carcinoma of the cervix: description of a technique and experience.

P. Rose, 1996, Gynecologic oncology.

Case report: the antenatal ultrasound diagnosis of megalourethra.

P. Rose, J. Scott, E. Dillon, 1994, Clinical radiology.

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.

P. Rose, F. Simpkins, J. Belinson, 2007, Gynecologic oncology.

A Phase I Study of Oral Topotecan and Pegylated Liposomal Doxorubicin (Doxil) in Platinum-Resistant Ovarian and Peritoneal Cancer

P. Rose, M. Smrekar, N. Fusco, 2008, American journal of clinical oncology.

Locally advanced cervical cancer

Peter G. Rose, P. Rose, 2001, Current opinion in obstetrics & gynecology.

Malignant peripheral primitive neuroectodermal tumor of the uterus

R. O’Toole, S. Qualman, P. Rose, 1987, Journal of surgical oncology.

prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

A. Godwin, H. Gray, H. Lankes, 2012 .

Primary resection of vaginal metastases with the Cavitron ultrasonic surgical aspirator in stage III endometrial carcinoma.

M. Piver, P. Rose, 1990, Gynecologic oncology.

Papillary squamotransitional cell carcinoma of the vagina.

M. Stoler, F. Abdul-Karim, P. Rose, 1998, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Initial surgical management of ovarian cancer

P. Rose, J. Knight, 2012 .

A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.

M. Brady, P. Rose, L. Van Le, 2016, Gynecologic oncology.

Multiple primary gynecologic neoplasms.

P. Rose, J. Boutselis, L. Sachs, 1987, American journal of obstetrics and gynecology.

Cisplatin and paclitaxel are associated with improved progression-free survival compared to cisplatin alone during interval debulking surgery with hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian cancer

L. Chambers, P. Rose, C. Michener, 2021, Gynecologic Oncology.

Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.

L. Chambers, P. Rose, C. Michener, 2021, Gynecologic oncology.

METHOTREXATE THERAPY FOR PERSISTENT ECTOPIC PREGNANCY AFTER CONSERVATIVE LAPAROSCOPIC MANAGEMENT

P. Rose, Stephen M. Cohen, 1990, Obstetrics and gynecology.

Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer

L. Chambers, P. Rose, C. Michener, 2020, Gynecologic Oncology.

Malignant struma ovarii: recurrence and response to treatment monitored by thyroglobulin levels.

F. Abdul-Karim, P. Rose, Burhanuddin Arafah, 1998, Gynecologic oncology.

Rationale and design of REWARD (revving-up exercise for sustained weight loss by altering neurological reward and drive): a randomized trial in obese endometrial cancer survivors.

Stephen M. Rao, M. Schluchter, J. Alberts, 2014, Contemporary clinical trials.

Patterns of Recurrence in Stage I Endometrioid Endometrial Adenocarcinoma With Lymphovascular Space Invasion

A. Mariani, A. Papadia, L. Landrum, 2013, International Journal of Gynecologic Cancer.

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

R. Burger, R. Wenham, D. Mutch, 2019, Obstetrics and gynecology.

Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy.

F. Abdul-Karim, P. Rose, F. Miraldi, 2001, Gynecologic oncology.

Phase I I S tudy o f L iposomal D oxorubicin i n P latinum- a nd Paclitaxel-Refra ctory E pithelial O varian C ancer

J. Hainsworth, P. Rose, C. Weissman, 2000 .

Surgery for recurrent ovarian cancer.

P. Rose, P G Rose, 2000, Seminars in oncology.

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.

P. Rose, H. Ball, K. Degeest, 2003, Gynecologic oncology.

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma

Maurie Markman, R. Ozols, D. Spriggs, 2009, Cancer.

Endometrial carcinoma.

P. Rose, 1996, New England Journal of Medicine.

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.

M. Birrer, R. Coleman, H. Lankes, 2011, Gynecologic oncology.

Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes

Bin Yang, L. Rybicki, P. Elson, 2019, International Journal of Gynecological Cancer.

Adenoid cystic carcinoma of the vulva: a radiosensitive tumor.

P. Rose, F. Reale, R. Hunter, 1991, Gynecologic oncology.

Significance of Cytologically Normal Endometrial Cells in Cervical Smears from Postmenopausal Women

F. Abdul-Karim, P. Rose, A. Rader, 2001, Acta Cytologica.

Locally advanced cervical carcinoma: the role of chemoradiation.

P. Rose, 1994, Seminars in oncology.

Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.

L. Rybicki, P. Rose, R. Vargas, 2021, Gynecologic oncology.

Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study.

P. Rose, M. Elshaikh, K. Albuquerque, 2015, Gynecologic oncology.

The impact of percent reduction in CA-125 levels on prediction of the extent of interval cytoreduction and outcome in patients with advanced stage cancer of müllerian origin treated with neoadjuvant chemotherapy

P. Rose, H. Mahdi, B. Nutter, 2015 .

Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group.

Joan L. Walker, P. DiSilvestro, P. Rose, 2006, Gynecologic oncology.

Clinical and radiological features of aberrant insertion of the common bile duct.

P. Rose, 1975, Clinical radiology.

Abnormal cervical cytology in the preoperative diagnosis of uterine papillary serous carcinoma: Earlier detection of a poor prognostic uterine cancer?

A. Fader, P. Rose, S. Ueda, 2011 .

Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers.

F. Abdul-Karim, A. Joehlin-Price, P. Rose, 2021, Immunotherapy.

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.

J. Thigpen, P. DiSilvestro, J. Java, 2016, Gynecologic oncology.

Stage IIB‐IVA Cancer of the Cervix

P. Rose, 2003, Cancer journal.

A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

S. Howell, H. Lankes, P. Rose, 2012, Gynecologic oncology.

Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials.

P. Rose, P. T. Lappas, 2000, Gynecologic oncology.

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

A. Godwin, A. Sood, C. Drescher, 2012, Gynecologic oncology.

Cervical Cancer: Advanced Stage and Relapse Treatment – Standard and Experimental Therapy

P. Rose, K. Levinson, 2013 .

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

M. Morgan, J. Java, P. Rose, 2016, Gynecologic oncology.

Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions

P. Rose, C. Michener, H. Mahdi, 2017, Journal of gynecologic oncology.

Using positron emission tomography imaging for maximum benefit in locally advanced cervical cancer.

P. Rose, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

13 Efficacy on individualized starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator-assessment (IA) in newly diagnosed advanced ovarian cancer (OC)

P. Follana, M. Mirza, H. Denys, 2020 .

Yolk sac tumor of the ovary associated with endometrioid carcinoma with metastasis to the vagina: a case report.

P. Rose, J. Brainard, J. Sawady, 2007, Gynecologic oncology.

Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC).

I. Vergote, M. Jones, P. Rose, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accuracy of frozen section for lymph node metastasis in patients undergoing radical hysterectomy for carcinoma of the cervix.

P. Rose, F. Reale, B. E. Nelson, 1993, Gynecologic oncology.

Recurrence in ovarian carcinoma stage I A/B grade 1 and 2 with and without chemotherapy

J. Bakkum-Gamez, P. Rose, R. Rocconi, 2007 .

Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing.

P. Rose, L. Petersen, D. Purpura, 2019, Anti-cancer drugs.

Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer.

P. Rose, Myra K. Feldman, K. Krivanek, 2023, JCO Precision Oncology.

A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.

R. Mannel, D. Dizon, P. Rose, 2014, Gynecologic oncology.

VAGINAL FIBROMYOMATA: TWO CASES WITH PREOPERATIVE ASSESSMENT, RESECTION, AND RECONSTRUCTION

S. B. Young, P. Rose, K. Reuter, 1991, Obstetrics and gynecology.

Palliative sclerosis of intra-abdominal cystic ovarian or peritoneal carcinoma.

P. Rose, V. Basile, 1999, Gynecologic oncology.

Time to surgery and its impact on survival in patients with endometrial cancer: A National cancer database study.

A. Khorana, L. Rybicki, P. Elson, 2019, Gynecologic oncology.

Arterial thrombosis in a gynecologic oncology patient: evaluation and management.

K. McCrae, P. Rose, A. Green, 2002, Gynecologic oncology.

CASE REPORT Arterial Thrombosis in a Gynecologic Oncology Patient: Evaluation and Management

K. McCrae, P. Rose, A. Green, 2002 .

Positron E mission T omography f or E valuating P ara-aortic Nodal M etastasis i n L ocally A dvanced C ervical C ancer Before S urgical S taging: A S urgicopathologi c S tudy

L. Adler, F. Abdul-Karim, P. Rose, 1999 .

Advanced uterine sarcoma; response to chemotherapy.

M. Piver, P. Rose, 1988, European journal of gynaecological oncology.

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

D. Alberts, S. Rubin, H. Gray, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.

T. Werner, P. Rose, M. Sill, 2015, Gynecologic oncology.

Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.

D. Alberts, M. Parmar, L. Stewart, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Racial disparity in the 30-day morbidity and mortality after surgery for endometrial cancer.

P. Rose, H. Mahdi, D. Lockhart, 2014, Gynecologic oncology.

CUSA splenorrhaphy for ovarian cytoreductive surgery.

P. Rose, B. Patsner, 1991, Gynecologic oncology.

Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma

S. Waggoner, P. Rose, A. Munkarah, 2015 .

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival

P. Escobar, A. Fader, P. Rose, 2013, Obstetrics and gynecology international.

Hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer: The Cleveland Clinic experience

L. Chambers, P. Rose, C. Michener, 2019, Gynecologic Oncology.

Commentary on “Is there a real standard for stage IVa cervical cancer?”

Shamshad Ali, P. Rose, 2011 .

Management Strategies for Recurrent Endometrial Cancer

P. Rose, E. Connor, 2018, Expert review of anticancer therapy.

A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study.

R. Mannel, N. Susumu, P. Rose, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LCK Regulates Homologous Recombination DNA Repair Identifying a New Target for Sensitizing PARP Inhibitors in HR Proficient Ovarian Cancer

K. McCrae, J. Lathia, E. Esakov, 2022, bioRxiv.

Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.

M. Morgan, M. Egorin, R. Mannel, 2008, Gynecologic oncology.